# The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

> **NCT07118319** · PHASE1 · RECRUITING · sponsor: **XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
- **DRUG:** Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)

## Key facts

- **NCT ID:** NCT07118319
- **Lead sponsor:** XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07118319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07118319, "The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07118319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*